Poseida Therapeutics, Inc.
DelistedCIK 1661460fmd_1GV4VEYB0AW0SEFQT7STR956V8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2024, 23 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Total revenues | – | – | 31 | 130 | 65 |
| Research and development | 60 | 104 | 137 | 153 | 157 |
| Total operating expenses | 86 | 127 | 173 | 190 | 194 |
| Operating income | (86) | (127) | (141) | (60) | (130) |
| Interest expense | 4 | 4 | 3 | 6 | 9 |
| Other non-operating income (expense) | 3 | 0 | 20 | 3 | 15 |
| Income before taxes | (87) | (130) | (125) | (63) | (123) |
| Income tax expense | 0 | 0 | 0 | 1 | 0 |
| Net income from continuing operations | (87) | (130) | (125) | (64) | (123) |
| Net income | (87) | (130) | (125) | (64) | (123) |
| Net income to common shareholders | (87) | (130) | – | – | – |